The German reimbursement authority released new reimbursement payment coding for Medovex's DenerveX™ system technology for the treatment of facet joint syndrome.
This new coding, effective immediately, allows hospitals and outpatient centers to receive reimbursement for use of the DenerveX System.
As noted by company leadership, this milestone may ease entry in additional countries, as Germany often leads in clinical adoption and the establishment of reimbursement guidelines.
DenerveX is designed to denervate and remove capsular tissue in one single procedure. The system comprises a single-use device plus power generator, is in final development stages and is not yet CE Marked nor FDA-cleared.
Source: Medovex Corp.